Study of Paragastric Block to Reduce Pain and Nausea After Laparoscopic Sleeve Gastrectomy Surgery

What this Trial Is About

Researchers are evaluating the effects of intraoperative paragastric block on early postoperative visceral pain, nausea, vomiting, and pain medicine needs in patients undergoing laparoscopic sleeve gastrectomy LSG for obesity. This prospective, randomized, double-blind controlled trial addresses the challenge of visceral pain after LSG, which can delay recovery and increase opioid use. Paragastric block targets nerve pathways near the stomach to potentially reduce these symptoms and improve early recovery. Participants will be randomly assigned to receive either a paragastric block with 20 mL of 0.5% bupivacaine or a sham block with 20 mL of isotonic saline. Both interventions involve injections at six specific sites near the stomach under laparoscopic guidance after gastric resection. The surgical technique, anesthesia, and postoperative care are standardized for all participants, and neither patients nor clinical staff will know which treatment is given. Participants will undergo postoperative evaluations at 0, 2, 6, and 12 hours after surgery to assess pain using a visual scale, nausea and vomiting severity, and ability to mobilize early. Pain medicine use and need for anti-nausea rescue treatments will be recorded within 24 hours. Safety and recovery will be monitored throughout, with a total study period covering the immediate postoperative day. The main outcome is pain measured shortly after surgery, with additional assessments of nausea, mobilization, and medication use.

Paragastric Block for Pain and PONV in Sleeve Gastrectomy